References
G. R. Tabeeva, Yu. É. Azimova, and E. S. Akarachkova, “Antiepileptic agents in the prophylactic of migraine: experience in the use of topiramate,” Farmatek, 14, 115–120 (2004).
J. L. Brandes, J. R. Saper, M. Diamond, et al., “Topiramate for migraine prevention. A randomized controlled trial,” J. Am Med. Assoc., 291, No. 8, 965–973 (2004).
P. J. Goadsby, “Migraine pathophysiology,” Headache, 45, Supplement 1, 14–24 (2005).
M. C. Kruit, M. A. van Buchem, P. A. M. Hofman, et al., “Migraine as a risk factor for subclinical brain lesions,” J. Am. Med. Assoc., 291, 427–434 (2004).
E. Loder and D. Biondi, “General principles of migraine management: the changing role of prevention, ” Headache, 45, Supplement 1, 33–37 (2005).
S. D. Silberstein, R. B. Lipton, and P. J. Goadsby Headache in Clinical Practice, Martin Dunitz, London (2002).
S. D. Silberstein, W. Neto, J. Schmitt, et al., “Topiramate in migraine prevention,” Arch. Neurol., 61, 490–495 (2004).
K. M. Welch, V. Nagesh, S. K. Aurora, and N. Gelman, “Periaqueductal gray matter dysfunction in migraine and chronic daily headache may be due to free radical damage,” J. Headache Pain, 2, 233–41 (2001).
K. M. Welch, “Brain hyperexcitability: the basis for antiepileptic drugs in migraine prevention,” Headache, 45, Supplement 1, 25–32 (2005).
H. S. White, “Molecular pharmacology of topiramate: managing seizures and preventing migraine,” Headache, 45, Supplement 1, 48–56 (2005).
Author information
Authors and Affiliations
Additional information
__________
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 106, No. 1, pp. 24–26, January, 2006.
Rights and permissions
About this article
Cite this article
Azimova, Y.É., Tabeeva, G.R. Prophylactic treatment of migraine with topamax: Long-term results. Neurosci Behav Physiol 37, 125–127 (2007). https://doi.org/10.1007/s11055-007-0159-4
Received:
Issue Date:
DOI: https://doi.org/10.1007/s11055-007-0159-4